A new monoclonal antibody against interleukin-4 and interleukin-13 has shown considerable potential to reduce asthma exacerbations, as well as the need for higher dose corticosteroid treatment. In view of the adverse effects associated with steroids, the promise of this treatment appears to be considerable. More here https://www.nejm.org/doi/full/10.1056/NEJMoa1804093 and here https://www.nejm.org/doi/full/10.1056/NEJMoa1804092
From the NEJM: Dupilumab Improves Severe Asthma
May 23, 2018